Asian markets ended mixed on Wednesday on optimism that US lawmakers could reach an agreement on a stimulus package before US election day. The market sentiments improved on reports that Moderna's CEO Stephane Bancel expects interim results from the firm's Covid-19 vaccine trial in November and that the US government could give an emergency use nod in December. Further, AstraZeneca Plc's Covid-19 vaccine trial in the United States is expected to resume as early as this week. Chinese shares ended marginally lower despite growing optimism about China’s economic recovery from virus outbreak, while the Chinese yuan surged to its strongest level against the dollar in more than two years.
Asian Indices | Last Trade | Change in Points | Change in % |
Shanghai Composite | 3,325.02 | -3.08 | -0.09 |
Hang Seng | 24,754.42 | 184.88 | 0.75 |
Jakarta Composite | 5,096.45 | -3.39 | -0.07 |
KLSE Composite | 1,492.40 | -18.57 | -1.23 |
Nikkei 225 | 23,639.46 | 72.42 | 0.31 |
Straits Times | 2,525.61 | -3.03 | -0.12 |
KOSPI Composite | 2,370.86 | 12.45 | 0.53 |
Taiwan Weighted | 12,877.25 | 14.88 | 0.12 |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: